Core Insights - Cytokinetics has awarded grants to two patient advocacy organizations to enhance communication and community outreach for hypertrophic cardiomyopathy (HCM) [2][3] Group 1: Grant Recipients and Initiatives - Camp Taylor received a grant to produce "Living with HCM: Youth Voices from Camp Taylor," a digital initiative that includes a five-part video series and an information toolkit aimed at educating families about HCM [4] - The Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation will develop "Think. Know. Act.: Cardiomyopathy Awareness in Canada," a six-month digital campaign to raise awareness of HCM symptoms and management among Canadian families [5] Group 2: Purpose and Impact of the Grant Program - The Cytokinetics Communications Grant Program aims to support patient advocacy organizations by providing resources for communications and outreach initiatives that are otherwise difficult to implement [6] - The program has been active for eight years, focusing on increasing awareness and community engagement for patient communities [6] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology and a pipeline of potential new medicines for cardiac muscle dysfunction [7] - The company’s product MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive HCM, with positive opinions for marketing authorization in the European Union expected in early 2026 [7][8]

Core Insights - Tenaya Therapeutics presented interim data from the MyClimb study, the largest noninterventional natural history study of pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the European Society of Cardiology Congress [1][2][5] Group 1: Study Overview - MyClimb study includes over 200 participants diagnosed with MYBPC3-associated HCM before age 18, with data collected from 27 centers across the U.S., Canada, Spain, and the UK [2][5] - The study aims to characterize the relationship between genotype and cardiac measures over time, initiated in 2021 [5] Group 2: Key Findings - 93% of participants had the nonobstructive form of HCM, which currently lacks approved treatment options [3] - Genetic inheritance patterns revealed distinct risk profiles among participants, with nearly all Homozygous group members dying or requiring heart transplants before age one [3] - Compound Heterozygous participants had a median diagnosis age of 2.9 years, with 63% experiencing heart failure-related hospitalizations [3] - Heterozygous children had a median diagnosis age of 6.5 years, with 27% facing heart failure-related hospitalizations [3] Group 3: Predictive Risk Factors - Left Ventricular Mass Index (LVMI) was identified as a significant predictor of risk, with every 10-unit increase associated with a 10% higher hazard of serious events [3] - Genetic profiles and LVMI may inform risk stratification and intervention strategies for pediatric patients [2][3] Group 4: Gene Therapy Development - TN-201 is a gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells, with initial data from the first three patients presented at a prior meeting [7] - The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Drug Designations from the FDA, indicating its potential significance in treating this condition [7] Group 5: Company Background - Tenaya Therapeutics focuses on developing curative therapies for heart disease, with a pipeline that includes TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy [8]